|
|
|
Patients should try to come to consult us personally, for
those that cannot do that, please send or fax to the professional group your recent symptoms, examination, analysis, early diagnose and case history (including patient's address, telephone number, height, weight), after discussion and diagnosis by the professional group, the treatment plan will be informed to the patient and he/she should receive treatment by postage. One can consult the professional group anytime during the treatment.
Tel: +380937434009
+380636018551
Fax:+80971147553
Email:yizi_06@yahoo.com.cn |
|
Miss Wang +380937434009 |
Miss Wang +380636018551 |
Email:yizi_06@yahoo.com.cn |
Address:Bei Xi Liu Lu Zhan Dian Zi Bo Shan Dong China |
Remittance/Payment |
|
|
Gufang Chinese medicine complicated diseases research center is located at Shan Dong Province Zi Bo City, ZhangDian Bei Xi Liu Road; Zi Bo is situated between LuZhong mountain area and LuBei champagne, located at a unique location, its south joins with TaiShan, its north is near by Yellow River, its west is connected with Spring City JiNan, its east is near by beach cities-QingDao, YanTai and WeiHai; it is one of ShanDong Province's five main tourist spots and it is one of the eight tourism city.
>>>more |
|
Dr. Wang Yong, character Shurun, of Han Nationality, is born to the Chinese medicine aristocratic family, he has inherited the essence of traditional Chinese medicine, he uses ancient secret remedies as the base and he complies, matches the results with the special characteristics of modern chronic diseases, high possibility contracted diseases, complicated diseases associated with drugs resistance, .
>>>more |
|
|
|
|
|
| TCM Is Entering The Mainstream In Terms Western Practitioners Understand |
|
| 2007-5-25 4:10:07 Viewed: [ Font:Large Medium Small] [ Close] |
|
|
The challenge of traditional medicine for Western practitioners
The trend of using traditional remedies as a substitute for chemically formulated drugs is set to continue with an industry growth rate of between 5 - 15 per cent a year, and much of it is no doubt due to the common layman belief that the more natural a product, the fewer the side effects.
Western practitioners, however, have long been uncomfortable with this assumption and this has resulted in many alternative treatments being sidelined as quack medicine lacking scientific basis. This stance is exacerbated by the dearth of research on most traditional remedies. Active ingredients and their mechanisms of action and interaction with concomitant treatments are unknown or not described in clinically accepted ways, while existing evidence based data often does not meet stringent Western criteria.
As a result the common reaction of skeptical Western medical practitioners is to follow a precautionary principle when advising patients and avoid recommending alternatives altogether. This helps to discourage uncritical enthusiasm for complementary medication among most patients and prevents the misuse of unproven or low-quality treatments. However this also denies many patients access to promising products, leaving certain medical needs unmet.
Bringing traditional medicine to the mainstream
It is possible, however, to incorporate alternative treatments into a Western medical framework - giving doctors a firm basis upon which to evaluate these treatments.
One such example is Neuroaid, a Traditional Chinese Medicine aimed at supporting stroke recovery, marketed by Moleac. Western medicine today offers a plethora of products and surgical treatments that deal with preventing the causes of stroke. However, its only offering for stroke patients after the hyper-acute stage comprises physiotherapy, which leaves recent stroke patients with only a 33% chance of full recovery. No Western drug offerings address the patient rehabilitation process.
When Moleac identified Neuroaid, clinical data had already been generated on the medication - a sizeable double-blind randomized clinical trial on over 600 patients had been conducted in China. The trial produced a 2.11 odd ratio in complete responders on a functional scale and very favorable outcomes on individual neurological deficit scores. The fact that the research had been conducted on patients several months after their stroke onset suggested Neuroaid helps stroke rehabilitation by improving the brain s neuroplasticity. No such drug exists in Western Pharmacopoeia.
This made the potential contribution Neuroaid could bring to stroke survivors an exciting prospect. However it was possible that the product s entirely herbal and natural formulation - engineered along the principles of Qi - would excite a lot of disbelief in the Western medical fields.
For this reason a Western approach to the development of Neuroaid as a mainstream product was adopted. Since it was already being successfully marketed for consumption in China as a proprietary medicine, the decision was made to focus on clinical development, instead of going back to animal models to evidence the precise mechanism of action.
The first step for this was to ensure the quality and stability of the product for safe consumption in a Western context. While the existing base of usage in China over several hundred thousands patients indicated the safety of NeuroAid, it was important to also ensure safety of consumption for patients receiving Western medical care.
As for stroke, the main concern is the risk of bleeding. Several studies were implemented which showed Neuroaid did not create such risks, even in combination with aspirin as an antiplatelet agent, or when taken over several weeks. Tests were also initiated and are now implemented on the product to ensure quality, including microbial analysis and heavy metal search. Good Manufacturing Practice quality standards are also enforced.
In addition, a review of existing efficacy data from China with Western criteria was conducted, focusing on improvement measured against familiar endpoints, keeping in mind that these trials were conducted using different methodology standards than those used in the West.
With solid safety and quality data in one hand and rigorously tested efficacy data, practitioners are now able to make an informed decision to advise patients on how to integrate NeuroAid into their recovery programs.
The next step is to implement more clinical trials in compliance with Western standards, to establish the exact efficacy of Neuroaid. Plans are in the pipeline for one such study, conducted by international neurologists, to be launched soon this year. Moleac is also exploring imagery markers to establish the actual effect of the drug in improving brain neuroplasticity.
|
|
|
